Ginkgo Bioworks Collaborated with Wisconsin Alumni Research Foundation to Discover GD2 CAR T-Cell Therapies for Cancer
Shots:
- Ginkgo & WARF collaborated to discover GD2 CAR T-cell therapies with improved persistence, proliferation, fitness & other functional properties using Ginkgo's high-throughput combinatorial CAR discovery & screening platform to improve efficacy
- Ginkgo will be in charge of designing & characterizing novel intracellular signaling domains that prevent the exhaustion of T-cells in the context of GD2 solid tumors using its platform
- To advance the development of novel CAR discovery, both intend to work together on the development of a pooled in vivo screening platform. Ginkgo will use its capabilities & expertise in mammalian cell engineering to enable high throughput CAR T-cell screening for the identification & improvement of next-generation therapeutic candidates for its partners
Ref: PR Newswire | Image: Ginkgo
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
